Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical's H-Shares Head for Biggest Fall Since Listing

05/05/2021 | 10:55pm EDT

By Ronnie Harui

Shares of Shanghai Fosun Pharmaceutical (Group) Co. and other Asia-based pharmaceutical companies tumbled Thursday after the U.S. said it would support a temporary waiver of intellectual property rights of Covid-19 vaccine makers, a move that could allow other companies to produce versions of the vaccines.

The Hong Kong-listed shares of Fosun Pharma, which distributes the vaccines developed by BioNTech SE in the Greater China region, fell as much as 26% in morning trade. Shares were last down 18% at 46.10 Hong Kong dollars, on pace for their biggest one-day drop since the company's initial public offering in 2012.

Shares of other Hong Kong-listed Covid-19 vaccine makers also slumped, with CanSino Biologics Inc. falling 21% to HK$289.00 and Sinopharm Group Co. dropping 10% to HK$23.15. In China, Fosun Pharma's A-shares were down 10% at 54.22 yuan.

The plunges tracked declines in the Chinese companies' American counterparts after the U.S. said it would support a proposal working its way through the World Trade Organization. Such a policy would waive the IP rights of vaccine makers to potentially enable companies in developing countries and others to manufacture their own versions of Covid-19 vaccines. The U.S. cited an urgent need to stem the pandemic.

Fosun Pharma's decline also follows a 20% jump in the share price Monday after the company posted a 47% rise in first-quarter net profit, largely because of higher drug sales and a low base of comparison due to the onset of the Covid-19 pandemic a year ago. Shares touched a record intraday high of HK$62.50 Tuesday and are up 24% this year and 62% over the past 12 months.

Write to Ronnie Harui at ronnie.harui@wsj.com

(END) Dow Jones Newswires

05-06-21 0055ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.48% 279.91 Delayed Quote.245.88%
CANSINO BIOLOGICS INC. -6.96% 270.2 End-of-day quote.53.09%
DJ INDUSTRIAL 0.06% 35075.55 Delayed Quote.14.56%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. -8.74% 71 End-of-day quote.31.51%
SINOPHARM GROUP CO., LTD. -1.36% 21.7 End-of-day quote.15.06%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.14% 6.48158 Delayed Quote.-0.34%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
MT
07/19SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement entering into the placing..
PU
07/19SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
07/14SINOVAC BIOTECH : Fosun-BioNTech COVID-19 vaccine completes China regulator revi..
RE
07/14MARKET CHATTER : BioNTech's COVID-19 Vaccine Advances to Administration Review i..
MT
07/14SHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolution proposed at the 2..
PU
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
RE
07/13Sisram Medical Limited completed the acquisition of Shanghai Foshion Medical ..
CI
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
RE
07/11SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma to Sell BioNTech Vaccines to Taiwan..
MT
More news
Financials
Sales 2021 39 915 M 6 158 M 6 158 M
Net income 2021 4 358 M 672 M 672 M
Net Debt 2021 15 917 M 2 456 M 2 456 M
P/E ratio 2021 42,0x
Yield 2021 0,73%
Capitalization 171 B 26 452 M 26 458 M
EV / Sales 2021 4,70x
EV / Sales 2022 4,20x
Nbr of Employees 32 258
Free-Float 58,8%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 71,00 CNY
Average target price 61,26 CNY
Spread / Average Target -13,7%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman